Insider Buying: Medicure (CVE:MPH) Director Buys C$19,560.00 in Stock

Medicure Inc. (CVE:MPH) Director Albert David Friesen acquired 16,300 shares of Medicure stock in a transaction on Friday, June 19th. The shares were bought at an average cost of C$1.20 per share, with a total value of C$19,560.00. Following the completion of the transaction, the director owned 550,767 shares of the company’s stock, valued at approximately C$660,920.40. This trade represents a 3.05% increase in their ownership of the stock.

Albert David Friesen also recently made the following trade(s):

• On Friday, June 19th, Albert David Friesen acquired 2,000 shares of Medicure stock. The stock was bought at an average cost of C$1.22 per share, for a total transaction of C$2,440.00.

Medicure Stock Performance

Shares of MPH stock traded up C$0.05 during midday trading on Monday, hitting C$1.25. 3,700 shares of the company were exchanged, compared to its average volume of 3,087. Medicure Inc. has a 52 week low of C$0.85 and a 52 week high of C$1.43. The firm has a market capitalization of C$13.04 million, a P/E ratio of -1.92 and a beta of 0.54. The firm’s 50 day moving average price is C$1.15 and its two-hundred day moving average price is C$1.15. The company has a debt-to-equity ratio of 6.34, a quick ratio of 1.28 and a current ratio of 1.04.

Medicure Company Profile

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.